Pfizer
Berta Rodriguez-Hervas is an accomplished professional in the field of artificial intelligence and machine learning, currently serving as the Chief AI & Analytics Officer at Pfizer. Prior experience includes holding the position of Vice President of Artificial Intelligence, Algorithms and ML Ops at Stellantis and serving as a Senior SW Engineering Manager/Principal Scientist focused on Computer Vision and Deep Learning at NVIDIA. Berta also contributed to advancements in Autopilot Computer Vision as both a Machine Learning Manager and Senior Machine Learning Engineer at Tesla. Academic credentials include a Doctor of Philosophy (PhD) in Electrical and Computer Engineering from The University of Texas at El Paso and studies at Michigan State University.
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.